FDA approves Hibsago (bepirovirsen) with NrtI therapy for adult chronic hepatitis B without cirrhosis; phase 3 trials show up to 20% functional cure at 72 weeks.

The recombinant zoster vaccine protects adults with HIV against cardiovascular complications such as incident heart failure ...

An infectious disease expert discusses using motivational interviewing and empathetic communication to address vaccine ...

META Older Latino adults show high motivation for RSV vaccination but face significant barriers to actual immunization.

Treatment-experienced patients with HIV and viremia achieve high virologic suppression with long-acting CAB/RPV.

Patient COVID-19 status does not significantly alter the microbiology of device-associated hospital-acquired infections or ...

Switching to a once-daily bictegravir/lenacapavir (BIC/LEN) single-tablet regimen is generally well tolerated through 48 ...

Are long-standing treatment habits holding us back? Key presentations at IDWeek 2026 highlight major shifts in managing influenza, severe staph bacteremia, difficult lung bugs, and microbiome health.

The Infectious Disease Advisor team will be covering emerging research and key takeaways from IDWeek 2026, as well as ...

During the 2024-2025 season, influenza vaccination effectively lowered the risk for hospitalization and severe inpatient outcomes among adults.

In people living with HIV and advanced solid tumors who are receiving antiretroviral therapy, treatment with nivolumab plus cabozantinib is safe.